Lipoproteins and the haemostatic system in atherothrombotic disorders

Bailliere's Best Practice and Research in Clinical Haematology

Volumn 12, Issue 3, 1999, Pages 555-575

  Miller, G J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Coagulation; Fibrinolysis; High density lipoproteins; Low density lipoproteins; Platelets; Very low density lipoproteins

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 7; HIGH DENSITY LIPOPROTEIN; HUMORAL ANTIBODY; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; THROMBIN; VERY LOW DENSITY LIPOPROTEIN;

ANTICOAGULATION; ARTERY THROMBOSIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD CLOTTING; HEMOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INFLAMMATION; LIPOPROTEIN BLOOD LEVEL; MACROPHAGE; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0033497051     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0040     Document Type: Article

References (198)

1. Duguid J B. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. Journal of Pathology. 58:1946;207-212.
2. Haust M D, Wyllie J C, More R H. Atherogenesis and plasma constituents. I, Demonstration of fibrin in the white plaque by the fluorescent antibody technique. American Journal of Pathology. 44:1964;255-267.
3. Chandler A B, Chapman I, Erhardt L R. Coronary thrombosis in myocardial infarction. Report of a workshop on the role of coronary thrombosis in the pathogenesis of acute myocardial infarction. American Journal of Cardiology. 34:1974;823-833.
4. Davies M J, Woolf N, Robertson W B. Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi. British Heart Journal. 38:1976;659-664.
5. Smith E B, Staples E M. Haemostatic factors in human aortic intima. Lancet. i:1981;1171-1174.
6. De Wood M A, Spores J, Notske R. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. New England Journal of Medicine. 303:1980;897-907.
7. Mizuno K, Satomura K, Miyamoto A. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. New England Journal of Medicine. 326:1992;287-291.
8. Stern D, Nawroth P, Handley D, Kisiel W. An endothelial cell-dependent pathway of coagulation. Proceedings of the National Academy of Sciences of the USA. 82:1985;2523-2527.
9. Marcum J A, McKenney J B, Rosenberg R D. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to endothelium. Journal of Clinical Investigation. 74:1984;341-350.
10. Owen W G, Esmon C T. Functional properties of an endothelial cell co-factor for thrombin-catalyzed activation of protein C. Journal of Biological Chemistry. 256:1981;5532-5535.
11. Stern D M, Brett J, Harris K, Nawroth P P. Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S. Journal of Cell Biology. 102:1986;1971-1978.
12. Bajaj M S, Kuppuswamy M N, Saito H. Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. Proceedings of the National Academy of Sciences of the USA. 87:1990;8869-8873.
13. Lupu C, Lupu F, Dennehy U. Thrombin induces the redistribution and acute release of tissue factor pathway inhibitor from specific granules within human endothelial cells in culture. Arteriosclerosis, Thrombosis and Vascular Biology. 15:1995;2055-2062.
14. Sevinsky J R, Rao L V, Ruf W. Ligand-induced protease receptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factor-dependent coagulation pathway. Journal of Cell Biology. 133:1996;293-304.
15. Broze G J, Warren L A, Novotny W F. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: insight into its possible mechanism of action. Blood. 71:1988;335-343.
16. aactivity in plasma requires factor X and an additional plasma component. Blood. 66:1985;204-212.
17. van Hinsbergh V WM, Binnema D, Scheffer M A. Production of plasminogen activators and inhibitors by serially propagated endothelial cells from adult human blood vessels. Arteriosclerosis. 7:1987;389-400.
18. Colucci M, Triggiani R, Cavallo L G, Semerano N. Thrombin infusion in endotoxin-treated rabbits reduces the plasma levels of plasminogen activator inhibitor: evidence for a protein C-mediated mechanism. Blood. 74:1989;1976-1982.
19. Palmer R MJ, Ashton D S, Moncada S. Vascular endothelial cells synthesize nitric oxide from L -arginine. Nature. 333:1988;664-666.
20. Moncada S, Higgs E A, Vane J R. Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet. i:1977;18-21.
21. Radomski M W, Palmer R MJ, Moncada S. The anti-aggregating properties of vascular endothelium: interaction between prostacyclin and nitric oxide. British Journal of Pharmacology. 92:1987;639-646.
22. Caplan B A, Schwartz C J. Increased endothelial turnover in areas of in vivo Evans blue uptake in the pig aorta. Atherosclerosis. 17:1973;401-417.
23. Schwartz S M, Benditt E P. Clustering of replicating cells in aortic endothelium. Proceedings of the National Academy of Sciences of the USA. 73:1976;651-653.
24. Clowes A W, Reidy M A, Clowes M M. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Laboratory Investigation. 49:1983;327-333.
25. Reidy M A. A reassessment of endothelial injury and arterial lesion formation. Laboratory Investigation. 53:1985;513-520.
26. Pober J S. Cytokine-mediated activation of vascular endothelium. Physiology and pathology. American Journal of Pathology. 133:1988;426-433.
27. Strober W, James S P. The interleukins. Pediatric Research. 24:1988;549-557.
28. Bevilacqua M P, Pober J S, Wheeler M E. Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leucocyte adhesion. American Journal of Pathology. 121:1985;394-403.
29. Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. Journal of Experimental Medicine. 163:1986;740-745.
30. Colucci M, Balconi G, Lorenzet R. Cultured human endothelial cells generate tissue factor in response to endotoxin. Journal of Clinical Investigation. 71:1983;1893-1896.
31. Moore K L, Andreoli S P, Esmon N L. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. Journal of Clinical Investigation. 79:1987;124-130.
32. Emeis J J, Kooistra T. Interleukin-I and lipopolysaccharide induce an inhibitor of tissue-type plasminogen activator in vivo and in cultured endothelial cells. Journal of Experimental Medicine. 163:1986;1260-1266.
33. Suffredini A F, Harpel P C, Parrillo J E. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. New England Journal of Medicine. 320:1989;1165-1172.
34. Nawroth P P, Stern D M, Kaplan K C, Nossel H L. Prostacyclin production by perturbed bovine aortic endothelial cells in culture. Blood. 64:1984;801-806.
35. Radomski M W, Palmer R MJ, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proceedings of the National Academy of Sciences of the USA. 87:1990;10 043-10 047.
36. Osborn L, Hession C, Tizard R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell. 59:1989;1203-1211.
37. Stolpen A H, Guinan E C, Fiers W, Pober J S. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganise human vascular endothelial cell monolayers. American Journal of Pathology. 123:1986;16-24.
38. Yellin M J, Brett J, Baum D. Functional interactions of T cells with endothelial cells: the role of CD40L-CD40-mediated signals. Journal of Experimental Medicine. 182:1995;1857-1864.
39. Henn V, Slupsky J R, Grafe M. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 391:1998;591-594.
40. Slupsky J R, Kalbas M, Willuweit A. Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thrombosis and Haemostasis. 80:1998;1008-1014.
41. Reuning U, Preissner K T, Muller-Berghaus G. Two independent binding sites on monolayers of human endothelial cells are responsible for interaction with coagulation factor VII and factor VIIa. Thrombosis and Haemostasis. 69:1993;197-204.
42. Morrissey J H, Macik B G, Neuenschwander P F, Comp P C. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood. 81:1993;734-744.
43. Bender J R, Sadeghi M MM, Mills L K. Endothelial cell adhesion molecule induction by α-thrombin. Journal of Cellular Biochemistry. 16A:1992;A202.
44. Bar-Shavit R, Kahn A, Wilner G D, Fenton J W. Monocyte chemotaxis: stimulation by specific exosite region in thrombin. Science. 220:1983;728-731.
45. Harlan J M, Thompson P J, Ross R R, Bowen-Pope D F. α-Thrombin induces release of platelet-derived growth factor-like molecules by cultured human endothelial cells. Journal of Cell Biology. 103:1986;1129-1133.
46. Prescott S M, Zimmerman G A, McIntyre T M. Human endothelial cells in culture produce platelet-activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) when stimulated with thrombin. Proceedings of the National Academy of Sciences of the USA. 81:1984;3534-3538.
47. McNamara C A, Sarembock I J, Gimple L W. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. Journal of Clinical Investigation. 91:1993;94-98.
48. Glenn K C, Carney D H, Fenton J W, Cunningham D D. Thrombin active site regions required for fibroblast receptor binding and initiation of cell division. Journal of Biological Chemistry. 255:1980;6609-6616.
49. Vu T-K H, Hung D T, Wheaton V I, Coughlin S R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 64:1991;1057-1068.
50. Stiernberg J, Redin W R, Warner W S, Carney D H. The role of thrombin and the thrombin receptor activating peptide (TRAP-508) in initiation of tissue repair. Thrombosis and Haemostasis. 70:1993;158-162.
51. Weksler B B, Ley C W, Jaffe E A. Stimulation of endothelial cell prostacyclin production by thrombin, trypsin and ionophore A 23187. Journal of Clinical Investigation. 62:1978;923-930.
52. Levin E G, Marzec U, Anderson J, Harker L A. Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells. Journal of Clinical Investigation. 74:1984;1988-1995.
53. Gelehrter R D, Sznycer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. Journal of Clinical Investigation. 77:1986;165-169.
54. Chambers R C, Dabbagh K, McAnulty R J. Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochemical Journal. 333:1998;121-127.
55. Smith E B, Staples E M. Plasma protein concentrations in interstitial fluid from human aortas. Proceedings of the Royal Society of Medicine. 217:1982;59-75.
56. Pritchard K A, Tota R R, Lin J H-C. Native low density lipoprotein. Endothelial cell recruitment of mononuclear cells. Arteriosclerosis and Thrombosis. 11:1991;1175-1181.
57. Gerrity R G. The role of the monocyte in atherogenesis. I. Transition of blood-borne monocytes into foam cells in fatty lesions. American Journal of Pathology. 103:1981;181-190.
58. Henriksen T, Mahoney E M, Steinberg D. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptor for acetylated low density lipoproteins. Proceedings of the National Academy of Sciences of the USA. 78:1981;6499-6503.
59. Henriksen T, Mahoney E M, Steinberg D. Enhanced macrophage degradation of biologically modified low density lipoprotein. Arteriosclerosis. 3:1983;149-159.
60. Morel D W, Di Corleto P E, Chisolm G M. Endothelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 4:1984;357-364.
61. Steinbrecher U P, Parthasarathy S, Leake D S. Modification of low density lipoprotein by endothelial cells involves lipid perodixation and degradation of low density lipoprotein phospholipids. Proceedings of the National Academy of Sciences of the USA. 83:1984;3883-3887.
62. Ball R Y, Brodley H, Brooks P N, Mitchinson M J. The production of ceroid by mouse peritoneal macrophages in vitro. British Journal of Experimental Pathology. 65:1984;719-724.
63. Stossel T P, Mason R J, Smith A L. Lipid peroxidation by human blood phagocytes. Journal of Clinical Investigation. 54:1974;638-645.
64. Cushing S D, Berliner J A, Valente A J. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proceedings of the National Academy of Sciences of the USA. 87:1990;5134-5138.
65. Drake T A, Hannani K, Fei H. MM-LDL induces tissue factor expression in cultured human endothelial cells. American Journal of Pathology. 138:1991;601-607.
66. Shih P T, Elices M J, Fang Z T. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta 1 integrins. Journal of Clinical Investigation. 103:1999;613-625.
67. Honda H M, Leitinger N, Frankel M. Induction of monocyte binding to endothelial cells by MM-LDL. Role of lipoxygenase metabolites. Arteriosclerosis, Thrombosis and Vascular Biology. 19:1999;680-686.
68. Senior R M, Shogen W F, Griffin G L, Wilner G D. Effects of fibrinogen derivatives upon the inflammatory response. Journal of Clinical Investigation. 77:1985;1014-1019.
69. Steinbrecher U P. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid decomposition products. Journal of Biological Chemistry. 262:1987;3603-3608.
70. Quinn M T, Parthasarathy S, Fong L G, Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proceedings of the National Academy of Sciences of the USA. 84:1987;2995-2998.
71. Parthasarathy S, Fong L G, Otero D, Steinberg D. Recognition of solubilized apoproteins from delipidated, oxidised low density lipoprotein (LDL) by the acetyl-LDL receptor. Proceedings of the National Academy of Sciences of the USA. 84:1987;537-540.
72. Rivers R PA, Hathaway W E, Weston W L. The endotoxin-induced coagulant activity of human monocytes. British Journal of Haematology. 30:1975;311-316.
73. ato monocytes. Journal of Clinical Investigation. 70:1982;526-535.
74. Schwartz B S, Levy G A, Curtiss L K. Plasma lipoprotein induction and suppression of the generation of cellular procoagulant activity in vitro. Journal of Clinical Investigation. 67:1981;1650-1658.
75. Schuff-Werner P, Claus G, Arastroy V W. Enhanced procoagulant activity (PCA) of human monocytes/macrophages after in vitro stimulation with chemically modified LDL. Atherosclerosis. 78:1989;109-112.
76. Brand K, Banka C L, Mackman N. Oxidised LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arteriosclerosis and Thrombosis. 14:1994;790-797.
77. van den Eijnden M MED, van Noort J T, Hollaar L. Cholesterol or triglyceride loading of human monocyte-derived macrophages by incubation with modified lipoproteins does not induce tissue factor expression. Arteriosclerosis, Thrombosis and Vascular Biology. 19:1999;384-392.
78. Tipping P G, Malliaros J, Holdsworth S R. Procoagulant activity expression by macrophages from atheromatous vascular plaques. Atherosclerosis. 79:1989;237-243.
79. Wilcox J N, Smith K M, Schwartz S M, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proceedings of the National Academy of Sciences of the USA. 86:1989;2839-2843.
80. Carson S D. Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VII and tissue factor. FEBS Letters. 132:1981;37-40.
81. Penn M S, Patel C V, Cui M-Z. LDL increases inactive tissue factor on vascular smooth muscle cell surfaces. Hydrogen peroxide activates latent cell surface tissue factor. Circulation. 99:1999;1753-1759.
82. Stiko-Rahm A, Hultgardh-Nilsson A, Regnstrom J. Native and oxidised LDL enhances production of PDGF AA and the surface expression of PDGF receptors in cultured human smooth muscle cells. Arteriosclerosis and Thrombosis. 12:1992;1099-1109.
83. Hessler J R, Morel D W, Lewis L J, Chisolm G M. Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis. 3:1983;215-222.
84. Cathcart M K, Morel D W, Chisolm G M. Monocytes and neutrophils oxidize low density lipoprotein making it cytotoxic. Journal of Leucocyte Biology. 38:1985;341-350.
85. Burrig K-F. The endothelium of advanced arteriosclerotic plaques in humans. Arteriosclerosis and Thrombosis. 11:1991;1678-1689.
86. Faggiotto A, Ross R. Studies of hypercholesterolemia in the nonhuman primate. II. Fatty streak conversion to fibrous plaque. Arteriosclerosis. 4:1984;341-356.
87. Hansson G K, Chao S, Schwartz S M, Reidy M A. Aortic endothelial cell death and replication in normal and lipopolysaccharide-treated rats. American Journal of Pathology. 121:1985;123-127.
88. Cohen R A, Shepherd J T, Vanhoutte P M. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science. 221:1983;273-274.
89. Shimokawa H, Vanhoutte P M. Hypercholesterolemia causes generalized impairment of endothelium-dependent relaxation to aggregating platelets in porcine arteries. Journal of the American College of Cardiology. 13:1989;1402-1408.
90. Hynes R O. The complexity of platelet adhesion to extracellular matrices. Thrombosis and Haemostasis. 66:1991;40-43.
91. Suzuki H, Shima M, Kamisue S. The role of platelet von Willebrand factor in the binding of factor VIII to activated platelets. Thrombosis Research. 92:1998;207-214.
92. Swords N A, Mann K G. The assembly of the prothrombinase complex on adherent platelets. Arteriosclerosis and Thrombosis. 13:1993;1602-1612.
93. Greengard J S, Heeb M J, Ersdal E. Binding of coagulation factor XI to washed human platelets. Biochemistry. 25:1986;3884-3890.
94. Joist J H, Baker R K, Schonfeld G. Increased in vivo and in vitro platelet function in type II- and type IV-hyperlipoproteinemia. Thrombosis Research. 15:1979;95-108.
95. Zahavi J, Betteridge J D, Jones N AG. Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia. American Journal of Medicine. 70:1981;59-64.
96. 2synthesis in type IIa hypercholesterolemic patients. Atherosclerosis. 79:1989;79-83.
97. Davi G, Averna M, Catalano I. Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation. 85:1992;1792-1798.
98. Broijersen A, Hamsten A, Eriksson M. Platelet activity in vivo in hyperlipoproteinemia - importance of combined hyperlipidemia. Thrombosis and Haemostasis. 79:1998;268-275.
99. Murphy E A, Mustard J F. Coagulation tests and platelet economy in atherosclerotic and control subjects. Circulation. 25:1962;114-125.
100. Harker L A, Slichter S J. Platelet and fibrinogen consumption in men. New England Journal of Medicine. 287:1972;999-1005.
101. Carvalho A CA, Colman R W, Lees R S. Platelet function in hyperlipoproteinemia. New England Journal of Medicine. 290:1974;434-438.
102. Corash L, Andersen J, Poindexter B J, Schaefer E J. Platelet function and survival in patients with severe hypercholesterolemia. Arteriosclerosis. 1:1981;443-448.
103. Di Minno G, Silver M J, Cerbone A M. Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis. 6:1986;203-211.
104. van Willegen G, Gorter G, Akkermann J-W N. Purified low-density lipoproteins increase the exposure of fibrinogen binding sites following stimulation with ADP. Thrombosis and Haemostasis. 69:1993;561.
105. Shattil S J, Bennett J S, Colman R W, Cooper R A. Abnormalities of cholesterol-phospholipid composition in platelets and low-density lipoproteins of human hyperbetalipoproteinemia. Journal of Laboratory and Clinical Medicine. 89:1977;341-353.
106. Schick B P, Schick P K. The effect of hypercholesterolemia on guinea pig platelets, erythrocytes and megakaryocytes. Biochimica et Biophysica Acta. 833:1985;291-302.
107. Shattil S J, Anaya-Galindo J, Bennett J. Platelet hypersensitivity induced by cholesterol incorporation. Journal of Clinical Investigation. 55:1975;636-643.
108. Tandon N, Harmon J T, Rodbard D, Jameison G A. Thrombin receptors define responsiveness of cholesterol-modified platelets. Journal of Biological Chemistry. 258:1983;11 840-11 845.
109. Renaud S, Kinlough R L, Mustard J F. Relationship between platelet aggregation and the thrombotic tendency in rats fed hyperlipidemic diets. Laboratory Investigation. 22:1970;339-343.
110. 2-independent platelet responses. Atherosclerosis. 88:1991;77-86.
111. Ardlie N G, Selley M L, Simons L A. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis. 76:1989;117-124.
112. Lowe G DO, Drummond M M, Third J LHC. Increased plasma fibrinogen and platelet-aggregates in type II hyperlipoproteinaemia. Thrombosis and Haemostasis. 42:1979;1503-1507.
113. Wessels P, du Heynes A P, Esterhuysen A J. Kinetics and in vivo distribution of In-111-labelled platelets and platelet function in familial hypercholesterolemia. Thrombosis and Haemostasis. 58:1987;811-816.
114. Strano A, Davi G, Averna M. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic patients. Thrombosis and Haemostasis. 48:1982;18-20.
115. Kowalska M A, Tuszynski G P, Capuzzi D M. Plasma lipoproteins mediate platelet adhesion. Biochemical and Biophysical Research Communications. 172:1990;113-118.
116. Desai K, Bruckdorfer K R, Hutton R A, Owen J S. Binding of apoE-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. Journal of Lipid Research. 30:1989;831-840.
117. Chemnitz J, Christensen B C. Repair in arterial tissue. Demonstration of fibrinogen/fibrin in normal and healing rabbit thoracic aorta by the indirect immunoperoxidase technique. Virchows Archiv A. Pathological Anatomy and Histology. 403:1984;163-171.
118. Smith E B. Fibrinogen, fibrin and fibrin degradation products in relation to atherosclerosis. Clinics in Haematology. 15:1986;355-370.
119. Bini A, Fenoglio J, Sobel J. Immunochemical characterization of fibrinogen, fibrin I and fibrin II in human thrombi and atherosclerotic lesions. Blood. 69:1987;1038-1045.
120. Knox P, Crooks S, Rimmer C S. Role of fibronectin in the migration of fibroblasts into plasma clots. Journal of Cell Biology. 102:1986;2318-2323.
121. Nuijens J H, Huijbregts C CM, Cohen M. Detection of activation of the contact system of coagulation in vitro and in vivo; quantitation of activated Hageman factor-C-1 inhibitor and kallikrein-C-1-inhibitor complexes by specific radioimmunoassays. Thrombosis and Haemostasis. 58:1987;778-785.
122. Bauer K A, Weiss L M, Sparrow D. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Journal of Clinical Investigation. 80:1987;1527-1534.
123. Bauer K A, Kass B L, ten Cate H. Detection of factor X activation in humans. Blood. 74:1989;2007-2015.
124. Bauer K A, Kass B L, ten Cate H. Factor IX is activated in vivo by the tissue factor mechanism. Blood. 76:1990;731-736.
125. Nossel H L, Yudelman I, Canfield R E. Measurement of fibrinopeptide A in human blood. Journal of Clinical Investigation. 54:1974;43-53.
126. 15-42sequence. Thrombosis Research. 25:1982;277-291.
127. Lowe G DO, Wood D A, Douglas J T. Relationships of plasma viscosity, coagulation and fibrinolysis to coronary risk factors and angina. Thrombosis and Haemostasis. 65:1991;339-343.
128. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. Journal of the American College of Cardiology. 9:1987;263-268.
129. Crutchley D J, McPhee G V, Terris M F, Canossa-Terris M A. Levels of three hemostatic factors in relation to serum lipids: monocyte procoagulant activity, tissue plasminogen activator, and type-1 plasminogen activator inhibitor. Arteriosclerosis. 9:1989;934-939.
130. Krauss R M. Low density lipoprotein imbalances and risk of coronary artery disease. Current Opinion in Lipidology. 2:1991;248-252.
131. Constantino M, Merskey C, Kudzma D J, Zucker M B. Increased activity of vitamin K-dependent clotting factors in human hyperlipoproteinaemia - association with cholesterol and triglyceride levels. Thrombosis and Haemostasis. 38:1977;465-474.
132. Fuller J H, Keen H, Jarrett R J. Haemostatic variables associated with diabetes and its complications. British Medical Journal. 2:1979;964-966.
133. Stirling Y, Woolf L, North W RS. Haemostasis in normal pregnancy. Thrombosis and Haemostasis. 52:1984;176-182.
134. ain hyperlipidaemia, with possible implications for ischaemic heart disease. British Journal of Haematology. 59:1985;249-258.
135. Folsom A R, Wu K K, Davis C E. Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 91:1991;191-205.
136. Mitropoulos K A, Miller G J, Reeves B EA. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis. 76:1989;203-208.
137. Elkeles R S, Chakrabarti R, Vickers M. Effect of treatment of hyperlipidaemia on haemostatic variables. British Medical Journal. 281:1980;973-974.
138. Simpson H CR, Mann J I, Meade T W. Hypertriglyceridaemia and hypercoagulability. Lancet. i:1983;786-790.
139. 1 + 2concentration, a marker of coagulability, in patients with coronary heart disease. Thrombosis and Haemostasis. 67:1992;503-506.
140. Miller G J, Martin J C, Mitropoulos K A. Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition. Atherosclerosis. 6:1991;163-171.
141. Silveira A, Karpe F, Blomback M. Activation of coagulation factor VII during alimentary lipemia. Arteriosclerosis and Thrombosis. 14:1994;60-69.
142. Marckmann P, Sandstrom B, Jespersen J. Dietary effects on circadian fluctuation in human blood coagulation factor VII and fibrinolysis. Atherosclerosis. 101:1993;225-234.
143. Sanders T AB, Oakley F R, Miller G J. Influence of n-6 versus n-3 polyunsaturated fatty acids in diets low in saturated fatty acids on plasma lipoproteins and hemostatic factors. Arteriosclerosis, Thrombosis and Vascular Biology. 17:1997;3449-3460.
144. Miller G J, Martin J C, Mitropoulos K A. Activation of factor VII during alimentary lipemia occurs in healthy adults and patients with congenital factor XII or factor XI deficiency, but not in patients with factor IX deficiency. Blood. 87:1996;4187-4196.
145. Silveira A, Karpe F, Johnsson H. In vivo demonstration in humans that large postprandial triglyceride-rich lipoproteins activate coagulation factor VII through the intrinsic coagulation pathway. Arteriosclerosis, Thrombosis and Vascular Biology. 16:1996;1333-1339.
146. Mitropoulos K A, Miller G J, Watts G F, Durrington P N. Lipolysis of triglyceride-rich lipoproteins activates factor XII: a study in familial lipoprotein-lipase deficiency. Atherosclerosis. 95:1992;119-125.
147. Radcliffe R, Bagdasarian A, Colman R W, Nemerson Y. Activation of bovine factor VII by Hageman factor fragments. Blood. 50:1977;611-617.
148. Connor W E. The acceleration of thrombus formation by certain fatty acids. Journal of Clinical Investigation. 41:1962;1199-1205.
149. Mibashan R S, Didisheim P. Activation of Hageman clotting factor (HF) by long-chain saturated fatty acids (LSFA). Federation Proceedings. 22:1963;163.
150. Botti R E, Ratnoff O D. The clot-promoting effect of soaps of long-chain saturated fatty acids. Journal of Clinical Investigation. 42:1963;1569-1577.
151. Mitropoulos K A, Esnouf M P. The autoactivation of factor XII in the presence of long-chain saturated fatty acids - a comparison with the potency of sulphatides and dextran sulphate. Thrombosis and Haemostasis. 66:1991;446-452.
152. Miller G J, Mitropoulos K A, Nanjee M N. Very low activated factor VII and reduced factor VII antigen in familial abetalipoproteinaemia. Thrombosis and Haemostasis. 80:1998;233-238.
153. Marckmann P, Sandstrom B, Jespersen J. Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids. Atherosclerosis. 80:1990;227-233.
154. Marckmann P, Sandstrom B, Jespersen J. Low-fat high-fiber diet favorably affects several independent risk markers of ischemic heart disease. Observations on blood lipids, coagulation, and fibrinolysis from a trial of middle-aged Danes. American Journal of Clinical Nutrition. 59:1994;935-939.
155. Brace L D, Gittler-Buffa C, Miller G J. Factor VII coagulant activity and cholesterol changes in premenopausal women consuming a long-term cholesterol-lowering diet. Arteriosclerosis and Thrombosis. 14:1994;1284-1289.
156. Miller G J, Martin J C, Webster J. Association between dietary fat intake and plasma factor VII coagulant activity - a predictor of cardiovascular mortality. Atherosclerosis. 60:1986;269-277.
157. Miller G J, Stirling Y, Howarth D J. Dietary fat intake and plasma factor VII antigen concentration. Thrombosis and Haemostasis. 73:1995;893.
158. Moyer M P, Tracy R P, Tracy P B. Plasma lipoproteins support prothrombinase and other procoagulant enzymatic complexes. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;458-465.
159. Barrowcliffe T W, Gray E, Kerry P J, Gutteridge J MC. Triglyceride-rich lipoproteins are responsible for thrombin generation induced by lipid peroxides. Thrombosis and Haemostasis. 52:1984;7-10.
160. Lawson J H, Kalafatis M, Stram S, Mann K G. A model for the tissue factor pathway to thrombin. I. An empirical study. Journal of Biological Chemistry. 269:1994;23 357-23 366.
161. Jones K C, Mann K G. A model for the tissue factor pathway to thrombin. II. A mathematical simulation. Journal of Biological Chemistry. 269:1994;23 367-23 373.
162. Mann K G. Biochemistry and physiology of blood coagulation. Thrombosis and Haemostasis. 82:1999;165-174.
163. Green D, Ryan C, Malandrucolo N, Nadler H L. Characterization of the coagulant activity of cultured human fibroblasts. Blood. 37:1971;47-51.
164. Giesen P L, Rauch V, Bohrmann B. Blood-borne tissue factor: another view of thrombosis. Proceedings of the National Academy of Sciences of the USA. 96:1999;2311-2315.
165. Carvalho de Sousa J, Bruckert E, Giral P. Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis. 19:1989;125-130.
166. Hoffman C J, Miller R H, Hultin M B. Correlation of factor VII activity and antigen with cholesterol and triglycerides in healthy young adults. Arteriosclerosis and Thrombosis. 12:1992;267-270.
167. Xu N, Dahlback B, Ohlin A-K, Nilsson A. Association of vitamin K-dependent coagulation proteins and C4b binding protein with triglyceride-rich lipoproteins of human plasma. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;33-39.
168. Mitropoulos K A, Esnouf M P. The prothrombin activation peptide regulates synthesis of the vitamin K-dependent proteins in the rabbit. Thrombosis Research. 57:1990;541-549.
169. MacCallum P K, Cooper J A, Howarth D J. Sex differences in the determinants of fibrinolytic activity. Thrombosis and Haemostasis. 79:1998;587-590.
170. Eliasson M, Evrin P-E, Lundblad D. Influence of gender, age and sampling time on plasma fibrinolytic variables and fibrinogen. Fibrinolysis. 7:1993;316-323.
171. Asplund-Carlson A, Hamsten A, Wiman B, Carlson L A. Relationship between plasma plasminogen activator inhibitor-activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normo- and hypertriglyceridaemic men. Diabetologia. 36:1993;817-825.
172. Byberg L, Siegbahn A, Berglund L. Plasminogen activator inhibitor-1 activity is independently related to both insulin sensitivity and serum triglycerides in 70-year-old men. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;258-264.
173. Margaglione M, Cappucci G, d'Addedda M. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis. Relation to environmental and genetic determinants. Arteriosclerosis, Thrombosis and Vascular Biology. 18:1998;562-567.
174. Welty F K, Mittleman M A, Wilson P W. Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population. Circulation. 95:1997;825-830.
175. Mussoni L, Maderna P, Camera M. Atherogenic lipoproteins and PAI-1 release by endothelial cells. Fibrinolysis. 4:1990;79.
176. Stiko-Rahm A, Wiman B, Hamsten A, Nilsson J. Secretion of plasminogen
177. Sironi L, Mussoni L, Prati L. Plasminogen activator inhibitor type-1 synthesis and mRNA expression in HepG2 cells are regulated by VLDL. Arteriosclerosis, Thrombosis and Vascular Biology. 16:1996;89-96.
178. Simon D I, Fless G M, Scanu A M, Loscalzo J. Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein (a) and low-density lipoprotein. Biochemistry. 30:1991;6671-6677.
179. Novotny W F, Brown S G, Miletich J P. Plasma antigen levels of the lipoprotein associated coagulation inhibitor in patient samples. Blood. 78:1991;387-393.
180. Hansen J B, Huseby K R, Huseby N E. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro. Thrombosis Research. 85:1997;413-425.
181. Caplice N M, Mueske C S, Kleppe L S. Presence of tissue factor pathway inhibitor in human atherosclerotic plaques is associated with reduced tissue factor activity. Circulation. 98:1998;1051-1057.
182. Marler R A, Kleiss A J, Griffin J H. Mechanism of action of human activated protein C, a thrombin-dependent anticoagulant enzyme. Blood. 59:1982;1067-1072.
183. Esmon C T. Molecular events that control the protein C anticoagulant pathway. Thrombosis and Haemostasis. 70:1993;29-35.
184. Conlan M G, Folsom A R, Finch A. Correlation of plasma protein C levels with cardiovascular risk factors in middle-aged adults: the Atherosclerosis Risk in Communities (ARIC) Study. Thrombosis and Haemostasis. 70:1993;762-767.
185. Woodward M, Lowe G DO, Rumley A. Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease. British Journal of Haematology. 97:1997;785-797.
186. European Heart Journal. 14:1993;8-17.
187. Rodeghiero F, Tosetto A. The VITA project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen: relationship with physiological variables and establishment of reference ranges. Thrombosis and Haemostasis. 76:1996;226-233.
188. MacCallum P K, Cooper J A, Martin J. Associations of protein C and protein S with serum lipid concentrations. British Journal of Haematology. 102:1998;609-615.
189. Griffin J H, Kojima K, Banka C L. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. Journal of Clinical Investigation. 103:1999;219-227.
190. Scanu A M, Fless G M. Lipoprotein (a): heterogeneity and biological relevance. Journal of Clinical Investigation. 85:1990;1709-1715.
191. McLean J W, Tomlinson J E, Kuang W-J. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature. 300:1987;132-137.
192. Lindahl G, Gersdorf E, Menzel H J. Variation in the size of human apolipoprotein (a) is due to a hypervariable region in the gene. Human Genetics. 84:1990;563-567.
193. Utermann G, Kraft H G, Menzel H J. Genetics of the quantitative Lp(a) lipoprotein trait: 1. Relation of Lp(a) glycoprotein phenotypes to Lp(a) lipoprotein concentration in plasma. Human Genetics. 78:1988;41-46.
194. Miles L A, Fless G M, Levin E G. A potential basis for the thrombotic risks associated with lipoprotein (a). Nature. 339:1989;301-303.
195. Loscalzo J, Weinfeld M, Fless G M, Scanu A M. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis. 10:1990;240-245.
196. Etingin O R, Hajjar D P, Hajjar K A. Lipoprotein (a) regulates plasminogen activator inhibitory expression in endothelial cells. Journal of Biological Chemistry. 266:1991;2459-2465.
197. Hajjar K A, Gavish D, Breslow J L, Nachman R L. Lipoprotein (a) modulation of endothelial cell surface fibrinolysis and its potential role in atherosclerosis. Nature. 339:1989;303-305.
198. Ezratty A, Simon D I, Loscalzo J. Lipoprotein (a) binds to human platelets and attenuates plasminogen binding and activation. Biochemistry. 32:1993;4628-4633.